ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.
Appointment of Kristine Peterson to Board of Directors
On September 13, 2017, the Board of Directors of Enanta Pharmaceuticals,Inc. announced that Kristine Peterson had been elected to serve as an independent director of the Company in the class of directors whose terms expire at Enanta’s 2018 Annual Meeting of Stockholders. This election increases the number of directors to seven. The Board of Directors also appointed Ms. Peterson as a member of the Compensation and Nominating and Corporate Governance Committees of the Board of Directors.
Ms. Peterson will receive the standard compensation for non-employee directors of Enanta, including retainer fees for Board and committee service and stock options, and will have the benefit of the Company’s standard form of indemnification agreement.
About ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA)
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease areas, including non-alcoholic steatohepatitis, respiratory syncytial virus and hepatitis B virus. Its product candidates include Paritaprevir (ABT-530), Glecaprevir (ABT-493), EDP-494 and EDP-239. Its paritaprevir is a protease inhibitor designed for use against hepatitis C virus (HCV). AbbVie Inc. has co-formulated ABT-493 with its second nonstructural protein 5A (NS5A) inhibitor, ABT-530, and is developing them as its next combination. It has demonstrated in replicon assays that its cyclophilin-targeting inhibitor, EDP-494, is a potent inhibitor of HCV replication in wild-type virus and in virus with resistance associated variants.